Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review.

Xiao, Chunmei; Xu, Fangye; Wang, Rong; Liang, Qi; Shen, Kai; Xu, Jiali; Liu, Lianke.

Afiliación

Xiao C; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Xu F; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Wang R; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Liang Q; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Shen K; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Xu J; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.
Liu L; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, People's Republic of China.

Onco Targets Ther ; 14: 5363-5372, 2021.

Article en En | MEDLINE | ID: mdl-34880628